[Inhaled bronchodilators and mucolytic agents in cystic fibrosis].
Identifieur interne : 000338 ( PubMed/Corpus ); précédent : 000337; suivant : 000339[Inhaled bronchodilators and mucolytic agents in cystic fibrosis].
Auteurs : P. Le Roux ; B. Le LuyerSource :
- Archives de pediatrie : organe officiel de la Societe francaise de pediatrie [ 0929-693X ] ; 2003.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Bronchodilator Agents, Deoxyribonucleases, Expectorants, Recombinant Proteins.
- drug therapy : Cystic Fibrosis.
- Administration, Inhalation, Humans.
Abstract
Poor clearance of airway secretions contributes to the pulmonary disease in cystic fibrosis (CF). Bronchodilator therapy might benefit in CF, but the efficacy is controversial. Effects of mucolytic agents have not been demonstrated conclusively. Only, efficacy of recombinant human deoxyribonuclease (rhDNase) is established with a rapid onset of benefit.
PubMed: 14671935
Links to Exploration step
pubmed:14671935Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Inhaled bronchodilators and mucolytic agents in cystic fibrosis].</title>
<author><name sortKey="Le Roux, P" sort="Le Roux, P" uniqKey="Le Roux P" first="P" last="Le Roux">P. Le Roux</name>
<affiliation><nlm:affiliation>Centre de ressources et de compétence dans la mucoviscidose, département de pédiatrie, groupe hospitalier, 55 bis, rue Gustave-Flaubert, 76600 Le Havre, France. pleroux@ch-havre.fr</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Le Luyer, B" sort="Le Luyer, B" uniqKey="Le Luyer B" first="B" last="Le Luyer">B. Le Luyer</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2003">2003</date>
<idno type="RBID">pubmed:14671935</idno>
<idno type="pmid">14671935</idno>
<idno type="wicri:Area/PubMed/Corpus">000338</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">[Inhaled bronchodilators and mucolytic agents in cystic fibrosis].</title>
<author><name sortKey="Le Roux, P" sort="Le Roux, P" uniqKey="Le Roux P" first="P" last="Le Roux">P. Le Roux</name>
<affiliation><nlm:affiliation>Centre de ressources et de compétence dans la mucoviscidose, département de pédiatrie, groupe hospitalier, 55 bis, rue Gustave-Flaubert, 76600 Le Havre, France. pleroux@ch-havre.fr</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Le Luyer, B" sort="Le Luyer, B" uniqKey="Le Luyer B" first="B" last="Le Luyer">B. Le Luyer</name>
</author>
</analytic>
<series><title level="j">Archives de pediatrie : organe officiel de la Societe francaise de pediatrie</title>
<idno type="ISSN">0929-693X</idno>
<imprint><date when="2003" type="published">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Inhalation</term>
<term>Bronchodilator Agents (therapeutic use)</term>
<term>Cystic Fibrosis (drug therapy)</term>
<term>Deoxyribonucleases (therapeutic use)</term>
<term>Expectorants (therapeutic use)</term>
<term>Humans</term>
<term>Recombinant Proteins (therapeutic use)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Bronchodilator Agents</term>
<term>Deoxyribonucleases</term>
<term>Expectorants</term>
<term>Recombinant Proteins</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Cystic Fibrosis</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Administration, Inhalation</term>
<term>Humans</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Poor clearance of airway secretions contributes to the pulmonary disease in cystic fibrosis (CF). Bronchodilator therapy might benefit in CF, but the efficacy is controversial. Effects of mucolytic agents have not been demonstrated conclusively. Only, efficacy of recombinant human deoxyribonuclease (rhDNase) is established with a rapid onset of benefit.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14671935</PMID>
<DateCreated><Year>2003</Year>
<Month>12</Month>
<Day>15</Day>
</DateCreated>
<DateCompleted><Year>2004</Year>
<Month>01</Month>
<Day>08</Day>
</DateCompleted>
<DateRevised><Year>2006</Year>
<Month>11</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0929-693X</ISSN>
<JournalIssue CitedMedium="Print"><Volume>10 Suppl 2</Volume>
<PubDate><Year>2003</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Archives de pediatrie : organe officiel de la Societe francaise de pediatrie</Title>
<ISOAbbreviation>Arch Pediatr</ISOAbbreviation>
</Journal>
<ArticleTitle>[Inhaled bronchodilators and mucolytic agents in cystic fibrosis].</ArticleTitle>
<Pagination><MedlinePgn>358s-363s</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Poor clearance of airway secretions contributes to the pulmonary disease in cystic fibrosis (CF). Bronchodilator therapy might benefit in CF, but the efficacy is controversial. Effects of mucolytic agents have not been demonstrated conclusively. Only, efficacy of recombinant human deoxyribonuclease (rhDNase) is established with a rapid onset of benefit.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Le Roux</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Centre de ressources et de compétence dans la mucoviscidose, département de pédiatrie, groupe hospitalier, 55 bis, rue Gustave-Flaubert, 76600 Le Havre, France. pleroux@ch-havre.fr</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Le Luyer</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
</Author>
</AuthorList>
<Language>FRE</Language>
<PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<VernacularTitle>Traitements inhalés bronchodilatateurs et fluidifiants dans la mucoviscidose.</VernacularTitle>
</Article>
<MedlineJournalInfo><Country>France</Country>
<MedlineTA>Arch Pediatr</MedlineTA>
<NlmUniqueID>9421356</NlmUniqueID>
<ISSNLinking>0929-693X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001993">Bronchodilator Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005100">Expectorants</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.1.-</RegistryNumber>
<NameOfSubstance UI="D003851">Deoxyribonucleases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000280" MajorTopicYN="N">Administration, Inhalation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001993" MajorTopicYN="N">Bronchodilator Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003550" MajorTopicYN="N">Cystic Fibrosis</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003851" MajorTopicYN="N">Deoxyribonucleases</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005100" MajorTopicYN="N">Expectorants</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
</MeshHeadingList>
<NumberOfReferences>46</NumberOfReferences>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year>
<Month>12</Month>
<Day>16</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2004</Year>
<Month>1</Month>
<Day>9</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2003</Year>
<Month>12</Month>
<Day>16</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">14671935</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/France/explor/LeHavreV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000338 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000338 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/France |area= LeHavreV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:14671935 |texte= [Inhaled bronchodilators and mucolytic agents in cystic fibrosis]. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:14671935" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a LeHavreV1
This area was generated with Dilib version V0.6.25. |